Fig. 4.
Fig. 4. BLR1/CXCR5 expression in B-cell chronic lymphocytic leukemia. / (A) BLR1/CXCR5 expression in peripheral blood of both CD19-positive B cells (left) and a subset of CD5-positive T cells (right). (B) BLR1/CXCR5 coexpression in the CD19/CD5-positive tumor cells of B-CLL. Flow cytometric detection used the 51505.111 CXCR5 monoclonal antibody with gating on the lymphocyte population by forward and side scatter properties.

BLR1/CXCR5 expression in B-cell chronic lymphocytic leukemia.

(A) BLR1/CXCR5 expression in peripheral blood of both CD19-positive B cells (left) and a subset of CD5-positive T cells (right). (B) BLR1/CXCR5 coexpression in the CD19/CD5-positive tumor cells of B-CLL. Flow cytometric detection used the 51505.111 CXCR5 monoclonal antibody with gating on the lymphocyte population by forward and side scatter properties.

Close Modal

or Create an Account

Close Modal
Close Modal